<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00622934</url>
  </required_header>
  <id_info>
    <org_study_id>425/195 13/4/86</org_study_id>
    <nct_id>NCT00622934</nct_id>
  </id_info>
  <brief_title>Relationship Between Erythropoietin Administration and Stress Responses in Trauma Patients</brief_title>
  <acronym>EPREX</acronym>
  <official_title>Relationship Between Clinical Recovery and Oxidative Stress and Inflammation Following Usage of Erythropoietin in Admitted Traumatic Patient In Intensive Care Unit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Erythropoietin decrease stress responses
      and inflammation in trauma patient.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transfusion of blood products has many disadvantages. Erythropoietin is used to increase red
      blood cells production and decrease such disadvantages.In some studies anti inflammatory
      effects is shown for Erythropoietin.

      One of the most problems in the intensive care unit is stress response. we are going to
      evaluate effects of erythropoietin on oxidative stress and inflammation in trauma patient in
      intensive care unit.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2007</start_date>
  <completion_date type="Anticipated">May 2008</completion_date>
  <primary_completion_date type="Anticipated">May 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>apachi 2 saps 30 days mortality</measure>
    <time_frame>untill discharge</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>30 days mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Multiple Trauma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erythropoietin</intervention_name>
    <description>300mg/kg erythropoietin 3 times on the first week of admission</description>
    <arm_group_label>1</arm_group_label>
    <other_name>EPREX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All multiple trauma patients&gt;16 years with informed consent

        Exclusion Criteria:

          -  Hypertension

          -  Allergy

          -  Erythroid leukemia

          -  Pregnancy and breast feeding

          -  Pre operative patient

          -  Severe cardiovascular and cerebrovascular diseases

          -  Thromboembolic disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MOJTABA MOJTAHEDZADE</last_name>
    <role>Study Chair</role>
    <affiliation>TUMS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MOSTAFA MOHAMMADY</last_name>
    <role>Principal Investigator</role>
    <affiliation>TUMS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MOJTABA MOJTAHED</last_name>
    <role>Study Director</role>
    <affiliation>TUMS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>mojtaba mojtahedzade</last_name>
    <phone>0982166701041</phone>
    <email>Mojtahed@sina.tums.ac.ir</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>mostafa mohammady</last_name>
    <phone>0982166735017</phone>
    <email>mohammady_m2007@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sina Hospital</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MOJTAHEDZADE</last_name>
      <phone>098216701041-9</phone>
    </contact>
    <contact_backup>
      <last_name>MOHAMMADY</last_name>
      <phone>0989126053454</phone>
    </contact_backup>
    <investigator>
      <last_name>MOSTAFA MOHAMMADY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>MOJTABA MOJTAHEDZADE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2008</study_first_submitted>
  <study_first_submitted_qc>February 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2008</study_first_posted>
  <last_update_submitted>November 17, 2010</last_update_submitted>
  <last_update_submitted_qc>November 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>Pharmaceutical Sciences Research Center Tehran University of Medical SCIENCES</name_title>
    <organization>Pharmaceutical Sciences Research Center Tehran University of Medical SCIENCES</organization>
  </responsible_party>
  <keyword>multiple trauma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Multiple Trauma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

